Towards effective, affordable protection against cervical cancer
Summary of story from the Guardian, September 8, 2011
According to a new study in the Journal of the National Cancer Institute, girls may need fewer doses of the human papillomavirus (HPV) vaccine than previously thought necessary to avoid cervical cancer.
School girls in the UK are currently administered three doses of the HPV vaccine, but findings suggest two or even one may offer sufficient protection.
This has potentially huge implications for treatment of the disease in poor countries where roughly 80% of cervical cancer deaths occur.
Currently vaccination is a long and costly process which makes it inaccessible to many of those who could directly benefit.
Aimée R Kreimer, of the division of cancer epidemiology and genetics at the National Cancer Institute in the US, and colleagues looked at the results of a trial of the vaccine in Costa Rica.
The researchers looked at 802 women who had either two vaccine or two placebo shots and 384 who received one dose – split fairly equally between vaccine and placebo.
Four years later, those who got two shots or only one shot appeared to have as much protection as those who got all three. While they warn that they don’t yet know the long term protection offered by one shot compared with three, the team says the findings may mean deprived countries could vaccinate more women for less money.
The study’s conclusion is supported by an editorial from Cosette Marie Wheeler, of the department of pathology and department of obstetrics and gynaecology at the University of New Mexico, who said:
“The age old adage of less is more may apply to HPV vaccination, and if so, the report of Kreimer et al represents an important step on the road to more effective and sustainable cervical cancer prevention programmes”.











